Management of Myelofibrosis: from Diagnosis to New Target Therapies.
Opinion Statement: Myelofibrosis (MF) is a clonal disorder of the pluripotent hematopoietic stem cell, whose clinical manifestations can be extremely heterogeneous, including cytopenias, organomegaly, constitutional symptoms, and cachexia. Median survival ranges from approximately 3.5 to 5.5 years;...
| Publicado en: | Current Treatment Options in Oncology Vol. 21; no. 6; pp. 1 - 15 |
|---|---|
| Autores principales: | , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Jun2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |